Ultrapure Dialysis Fluid: A New Standard for Contemporary Hemodialysis

Authors Information
Article Notes and Dates
To Cite : Canaud B, Lertdumrongluk P. Ultrapure Dialysis Fluid: A New Standard for Contemporary Hemodialysis, Nephro-Urol Mon. 2012 ;4(3):519-523. doi: 10.5812/numonthly.3060.
1. Introduction
2. UPDF as a Surrogate for Sterile and Non-Pyrogenic Dialysis Fluid
3. UPDF is Easily Produced by Online Cold Sterilization
4. UPDF is Justified by Operative Conditions of Contemporary Dialysis
5. UPDF Prevents Inflammation and Its Deleterious Biological and Clinical Consequences
6. UPDF Reduces Morbidity and Mortality in HD Patients
7. UPDF is Technically and Economically Feasible for All Dialysis Facilities
8. UPDF Will Be the Basic Requirement for Developing Innovative Dialysis Modalities for Future Renal Replacement Therapy
Acknowledgements
Footnotes
References
  • 1. Canaud B, Wabel P, Tetta C. Dialysis prescription: A modifiable risk factor for chronic kidney disease patients. Blood Purif. 2010; 29(4): 366-74[DOI][PubMed]
  • 2. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63(5): 1934-43[DOI][PubMed]
  • 3. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis. 2004; 44(5 Suppl 2): 16-21[DOI][PubMed]
  • 4. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003; 14(12): 3270-7[DOI][PubMed]
  • 5. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006; 11(1): 36-41[DOI][PubMed]
  • 6. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease- -what have we learned in 10 years? Semin Dial. 2010; 23(5): 498-509[DOI][PubMed]
  • 7. Mion CM, Canaud B, Garred LJ, Stec F, Nguyen QV. Sterile and pyrogen-free bicarbonate dialysate: a necessity for hemodialysis today. Adv Nephrol Necker Hosp. 1990; 19: 275-314[DOI][PubMed]
  • 8. Bommer J, Jaber BL. Ultrapure dialysate: facts and myths. Semin Dial. 2006; 19(2): 115-9[DOI][PubMed]
  • 9. Canaud B, Bosc JY, Leray H, Morena M, Stec F. Microbiologic purity of dialysate: rationale and technical aspects. Blood Purif. 2000; 18(3): 200-13[DOI][PubMed]
  • 10. Ward RA. Ultrapure dialysate: a desirable and achievable goal for routine hemodialysis. Semin Dial. 2000; 13(6): 378-80[DOI][PubMed]
  • 11. Canaud B, Peyronnet P, Armynot A, Nguyen Q, Attisso M, Mion C. Ultrapure water: a need for future dialysis. Nephrol Dial Transplant. 1986; 1: 110[DOI]
  • 12. Canaud B, Mion C. Replacement of renal function by dialysis. 1996; : 231-55[DOI]
  • 13. Canaud B, Bosc JY, Leray H, Stec F, Argiles A, Leblanc M, et al. Online haemodiafiltration: state of the art. Nephrol Dial Transplant. 1998; 13: 3-11[DOI][PubMed]
  • 14. Section III. Biocompatibility. Nephrol Dial Transplant. 2002; 17: 32-44[PubMed]
  • 15. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial. 2011; 24(1): 1-4[DOI][PubMed]
  • 16. Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs. 1999; 23(1): 37-43[DOI][PubMed]
  • 17. Lonnemann G. Should ultra-pure dialysate be mandatory? Nephrol Dial Transplant. 2000; 15: 55-9[DOI][PubMed]
  • 18. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.13 Analysis of patient and graft survival. Nephrol Dial Transplant. 2000; 17: 60-7[PubMed]
  • 19. Kawanishi H, Masakane I, Tomo T. The new standard of fluids for hemodialysis in Japan. Blood Purif. 2009; 27: 5-10[DOI][PubMed]
  • 20. ANSI/AAMI/ISO 11663:2009, Quality of dialysis fluid for hemodialysis and related therapies.
  • 21. Rahmati MA, Homel P, Hoenich NA, Levin R, Kaysen GA, Levin NW. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs. 2004; 27(8): 723-7[PubMed]
  • 22. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol. 2000; 53(6): 452-9[PubMed]
  • 23. Arizono K, Nomura K, Motoyama T, Matsushita Y, Matsuoka K, Miyazu R, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif. 2004; 22: 26-9[DOI][PubMed]
  • 24. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000; 15(8): 1207-11[DOI][PubMed]
  • 25. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant. 2003; 18-22[DOI][PubMed]
  • 26. Hsu PY, Lin CL, Yu CC, Chien CC, Hsiau TG, Sun TH, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol. 2004; 17(5): 693-700[PubMed]
  • 27. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis. 2009; 16(2): 94-100[DOI][PubMed]
  • 28. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011; 26(8): 2641-8[DOI][PubMed]
  • 29. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif. 2005; 23(4): 311-6[DOI][PubMed]
  • 30. Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, et al. Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif. 2009; 28(1): 29-39[DOI][PubMed]
  • 31. Tao J, Sun Y, Li X, Li H, Liu S, Wen Y, et al. Conventional versus ultrapure dialysate for lowering serum lipoprotein(a) levels in patients on long-term hemodialysis: a randomized trial. Int J Artif Organs. 2010; 33(5): 290-6[PubMed]
  • 32. Schiffl H, Lang SM. Effects of dialysis purity on uremic dyslipidemia. Ther Apher Dial. 2010; 14(1): 5-11[DOI][PubMed]
  • 33. Guo LL, Pan Y, Zhu XJ, Tan LY, Xu QJ, Jin HM. Conventional, but not high-purity, dialysate-induced monocyte apoptosis is mediated by activation of PKC-delta and inflammatory factors release. Nephrol Dial Transplant. 2011; 26(5): 1516-22[DOI][PubMed]
  • 34. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003; 18(7): 1272-80[DOI][PubMed]
  • 35. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant. 2002; 17(10): 1814-8[DOI][PubMed]
  • 36. Vilar E, Fry AC, Wellsted D, Tattersall JE, Greenwood RN, Farrington K. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol. 2009; 4(12): 1944-53[DOI][PubMed]
  • 37. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16(9): 1863-9[DOI][PubMed]
  • 38. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther. 2003; 10(3): 155-69[DOI][PubMed]
  • 39. Lonnemann G, Koch KM. Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol. 2002; 13-7[PubMed]
  • 40. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuk M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int. 1997; 52(4): 1096-101[DOI][PubMed]
  • 41. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int. 1999; 55(1): 286-93[DOI][PubMed]
  • 42. Ouseph R, Jones S, Dhananjaya N, Ward RA. Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant. 2007; 22(8): 2269-75[DOI][PubMed]
  • 43. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008; 3(2): 505-21[DOI][PubMed]
  • 44. Locatelli F, Altieri P, Andrulli S, Bolasco P, Sau G, Pedrini LA, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol. 2010; 21(10): 1798-807[DOI][PubMed]
  • 45. Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch KM, Floege J. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int. 1997; 52(4): 1077-83[DOI][PubMed]
  • 46. Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant. 2000; 15(6): 840-5[DOI][PubMed]
  • 47. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron. 2002; 91(3): 452-5[DOI][PubMed]
  • 48. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int. 2006; 69(11): 2087-93[DOI][PubMed]
  • 49. Jirka T, Cesare S, Di Benedetto A, Perera Chang M, Ponce P, Richards N, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int. 2006; 70(8): 1524; author reply -5[PubMed]
  • 50. Vinhas J, Vaz Á, Barreto C, Assunção J. Survival advantage of patients on haemodiafiltration is independent of dialysis dose and patient characteristics: data from a single centre. Port J Nephrol Hypert. 2007; 21(4): 287-92
  • 51. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant. 2008; 23(7): 2337-43[DOI][PubMed]
  • 52. Martin K, Laydet E, Canaud B. Design and technical adjustment of a water treatment system: 15 years of experience. Adv Ren Replace Ther. 2003; 10(2): 122-32[DOI][PubMed]
  • 53. Penne EL, Visser L, van den Dorpel MA, van der Weerd NC, Mazairac AH, van Jaarsveld BC, et al. Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice. Kidney Int. 2009; 76(6): 665-72[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Nephro-Urology Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check